

November 22, 2017

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street,  
Mumbai - 400 001

**The National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E)  
Mumbai - 400 051

Dear Sirs,

**Re.: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Pursuant to the provisions of Regulation 30 read with Schedule III to the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to intimate that Drug Discovery and Development Solutions Limited, Singapore ('DDDSL'), a wholly-owned subsidiary company, has entered into Stock Purchase Agreement for acquiring entire Equity Share capital of Jubilant Discovery Services Inc., USA ('JDSI') on November 21, 2017, subject to applicable laws.

JDSI is a step-down subsidiary whose share capital is held by Jubilant Biosys Limited, a step-down subsidiary of the Company.

After the said acquisition of shares, JDSI shall become a wholly-owned subsidiary of DDDSL.

Details pursuant to Regulation 30 are given in **Annexure-A**.

We request you to take the same on record.

Thanking you,

Yours faithfully,  
For Jubilant Life Sciences Limited

  
Rajiv Shah  
Company Secretary

Encl.: As above



**A Jubilant Bhartia Company**

OUR VALUES



**Jubilant Life Sciences Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
www.jubl.com

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223,  
UP, India  
CIN : L24116UP1978PLC004624



**Annexure-A**

**Details of Acquisition of Equity Shares by wholly-owned subsidiary**

Sr. No.	Particulars	Details
1.	Name of the target entity, details in brief such as size, turnover etc.	Jubilant Discovery Services Inc. ('JDSI'), USA  <u>FY 2016-17:</u> <ul style="list-style-type: none"> <li>• <u>Turnover:</u> USD 2,623,973</li> <li>• <u>EBITDA:</u> USD 209,445</li> </ul>
2.	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length"	<p>As Jubilant Life Sciences Limited (the 'Company') is not a party to the transaction, it is not considered as a Related Party Transaction. The transaction is being executed on arm's length basis.</p> <p>The target entity, JDSI is a step-down subsidiary whose share capital is held by Jubilant Biosys Limited, a step-down subsidiary of the Company.</p> <p>The promoters of the Company, Mr. Shyam S. Bhartia and Mr. Hari S. Bhartia, together with the companies controlled by them, hold 33% equity shares of Jubilant Biosys Limited ('the Seller').</p>
3.	Industry to which the entity being acquired belongs	Contract Research (Drug Discovery Solutions)
4.	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Consolidation of Drug Discovery and Development entities of Jubilant Life Sciences group
5.	Brief details of any governmental or regulatory approvals required for the acquisition	-
6.	Indicative time period for completion of the acquisition	On or before December 31, 2017
7.	Nature of consideration - whether cash consideration or share swap and details of the same	Cash consideration
8.	Cost of acquisition or the price at which the shares are acquired	2,860,941.05 USD





9.	Percentage of shareholding / control acquired and / or number of shares acquired;	3,485 Equity Shares of USD 100 each at USD 820.93 aggregating to USD 2,860,941.05 i.e. 100% holding of Equity Shares.
10.	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	<p>The relevant details of JDSI are given below:</p> <ul style="list-style-type: none"><li>• <u>Products/line of business:</u> Drug Discovery Solutions</li><li>• <u>Date of incorporation:</u> February 13, 2006</li><li>• <u>Turnover of last three years:</u>  2014-15: USD 3,818,310 2015-16: USD 2,021,870 2016-17: USD 2,623,973</li><li>• <u>Country in which JDSI has presence:</u> USA</li><li>• <u>Any other significant information:</u> NIL</li></ul>

